|By Marketwired .||
|June 10, 2014 07:01 AM EDT||
TUCSON, AZ -- (Marketwired) -- 06/10/14 -- Today HTG Molecular Diagnostics announced the availability of HTG EdgeSeq miRNA Whole Transcriptome Assay for measuring the expression of 2,275 human microRNAs (miRNAs) described in the miRBase v20 database. The assay measures expression from very small, sometimes difficult sample types such as formalin-fixed, paraffin-embedded (FFPE) tissues and plasma. Automated on the HTG Edge System, HTG Edge miRNA Whole Transcriptome Assay couples HTG's proprietary nuclease protection chemistry with next-generation-sequencing (NGS).
"The assay is ideal for the characterization of miRNA expression patterns from a wide variety of sample types, including FFPE, blood, plasma and serum, PAXgene and cell lines. Sample and library preparation are automated on our HTG Edge System for faster, easier quantification for high-fidelity miRNA expression profiling," stated Debrah Thompson, HTG's Director of Research. "The solution is ideal for laboratories seeking to further leverage capacity of their existing NGS in a new way, and because we've simplified the bioinformatics back-end, laboratories can add this capability very quickly," Dr. Thompson added.
"With HTG EdgeSeq we've combined the high-specificity of our nuclease protection chemistry with the broad dynamic range and exquisite sensitivity of next-generation-sequencing, making this the next big thing in digital gene expression. Even with challenging sample types such as FFPE, HTG EdgeSeq miRNA Whole Transcriptome Assay eliminates the need to extract RNA with our lysis-only, extraction-free chemistry," commented TJ Johnson, HTG Molecular Chief Executive Officer. "Sample and library prep is fully automated on the HTG Edge System, simplifying workflow, reducing hands-on-time, and resulting in faster turnaround times," Mr. Johnson added.
Headquartered in Tucson, Arizona, HTG Molecular Diagnostics' mission is to provide simple, cost effective solutions for accurate RNA testing. In 2013 the company commercialized its Edge instrument platform and a portfolio of mRNA RNA assays that leverage HTG's proprietary nuclease protection chemistry. HTG Edge System capabilities have been expanded to fully automate sample and targeted library preparation for next-generation sequencing. Additional information is available at www.htgmolecular.com.